These results suggest that this class of compounds warrant further investigation as candidate tau-based therapeutics to alter the onset or progression of tau dysfunction and pathology in Alzheimer's disease and other tauopathies. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.